GlobalData CEO sells £22.5 million sharesEveryman director Rosehill ups stakeBioventix CEO sells £2.6 million sharesMichael Danson, CEO of GlobalData (DATA:AIM), a London-based data analytics and consulting company has sold 11,194,030 shares at 201p for a total value of £22.5 million on 31 January.Non-executive director Peter Harkness has sold 235,700 shares at 201p for a total value of £473,7

- H1 sales up 25%, pre-tax profit up 27%, dividend up 20%- Significant growth in heart attack antibody troponin- Exciting new antibodies in development for Alzheimer's High-affinity monoclinal antibodies developer and supplier Bioventix (BVXP:AIM) increased revenues by 25% to £5.9 million and pre-tax profit by 27% to £4.5 million in the first half to 31 December 2022.The board upped the first ha

Following the professionals and mirroring what they do has long been a strategy used by some investors.John from Ruislip is among that group and follows the strategies of three well-known UK fund managers - Terry Smith, Nick Train and Keith Ashworth-Lord.He believes 'they all clearly define their strategies, so they are easy to copy, they act as my mentors', and has been in contact with all three.

The brains behind two of the best performing UK equity funds in recent years is to launch its first investment trust, targeting smaller companies that look cheap and which have the right characteristics to grow for many years to come.Sanford DeLand-run Buffettology Smaller Companies Investment Trust is seeking to raise at least £100 million with its IPO offer open to both retail and institutional

The appeal of a growth company is easy to understand - when we put our money into a business which we expect to grow rapidly we can imagine the worth of our investment growing fast too.Many of today's largest companies were once small or medium-sized operations which have expanded their business by targeting a buoyant market or identifying a particularly profitable niche.And growth as an investmen

Income is a big motivating factor for people to invest in the markets. The idea of securing a regular stream of cash which can be used to pay the bills or reinvested to help boost capital returns is an attractive one.However, this income is not guaranteed and the last two months or so of dividend cuts, suspensions and deferrals have seen billions of pounds worth of payouts from UK stocks taken off

With just over 20 years' investing experience under his belt, Dave from Staffordshire has honed his skills to be able to run a concentrated portfolio entirely out of small, medium and large cap stocks.The 46-year-old public sector worker first began putting money into the markets in 1999. 'I opened an ISA possibly at the worst time to start investing,' he says. 'Fortunately I topped it up at oppor

London's FTSE 100 firms 37.4 points to 7,272 on Friday, boosted by miners which are up on hopes that the US and China are making progress with trade talks. Continued strength with oil prices is also giving the blue chip benchmark support with both BP (BP.) and Royal Dutch Shell (RDSA) ticking higher.Drugs giant AstraZeneca (AZN) cheapens 4.2% to £62.21, despite inking a $6.9bn agreement with Daii

Typically people invest in small cap biotechnology and pharmaceutical stocks in the hope they can enjoy returns of many times their initial investment as the share price reacts to the discovery of the next wonder drug.However, stories like these are actually few and far between and lots of companies in this space instead burn through their cash quickly and end up going bust.Profitable businesses a

Antibodies developer Bioventix (BVXP:AIM) achieved better than expected sales for its financial year to 30 June, up 31% to £7.2m. The results were particularly boosted by its Vitamin D antibody vitD3.5H10 for deficiency testing.Full year earnings per share also beat expectations by 7%, which was driven by higher sales, gross margins and a lower tax charge.Shareholders are being rewarded with a 40

In some ways, investment styles are a bit like the pick 'n' mix section of a well-stocked sweet shop. Cola bottles will suit some tastes, others may prefer cola cubes; pear drops, rhubarb and custard or humbugs could prove the fancy of a completely different group. So it is with investment, every investor must make their own choices based on their own feelings towards risk, time frame and an assor

Investing in smaller companies can be higher risk than putting money to work in well-established blue chip businesses. Yet with additional risk comes the potential for bigger rewards, as there are few better investments than businesses that can grow over the long-term.Spotting the right smaller companies is the difficult bit. One way to mitigate single stock risk is to put your money to work with

Stonegate Pub eyes IPOStonegate Pub, the UK's fourth-largest managed pub company, is thought to be considering a £1 billion stock market float early next year. The Slug & Lettuce and Yates's owner recently bought 53 pubs from Lone Star Funds for a rumoured £100 million, taking its estate to 665 pubs. (EP)AFC makes grid deliveryAlkaline fuel cell specialist AFC Energy (AFC:AIM) has delivered its

Antibody developer Bioventix (BVXP:AIM) is one of London's biggest risers in early trading on Friday after 'significantly' beating profit expectations. Shares in the £55.5 million cap shot up 17.6% to £11.00 following the upbeat update for the year to 30 June, which has forced analysts to upgrade their forecasts.Revenues for the period are now expected to be above £4.2 million. Analysts at brok

UK share indexes surrender the rump of yesterday's gains in early trading on what looks likely to be a relatively quiet Friday session. Blue-chip retailers are out of favour, as are several insurers and banks. Asia bourses eased overnight, while Wall Street was mixed.The FTSE 100 is off around 85 points, or 1.3%, at 6,111, while midcaps are down similarly, the FTSE 250 falling 161 points to 16,926

The stock market's smallest and riskiest companies have always held fascination for private investors. On the premise that 'elephants don't gallop, but fleas leap,' to borrow Jim Slater's often quoted phrase, it's easier for a tiny company to double its size, and investor's money, than for a big one. Let's face it, a blue chip company worth £1 billion will find it much harder to double or even tr